
Nabla Bio Inc Profile last edited on: 2/11/2022
CAGE: 8LN41
UEI: P7MAMKMQQM39
Business Identifier: Autoverse platform of proprietary biologically informed machine-learning co-developing antibody drugs Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Suffolk
Congr. District: 07
County: Suffolk
Public Profile
A spin-out from Harvard, Nabla Bio is structured around development of novel proteins intended for medical and industrial applications. Applying AI technology to antibody design, the company's supernatural proteins are extrapolated from insights learned from billions of natural ones and are enhanced through diverse protein variants through numerous experiments, enabling clients to carry out implementations involving complex measurements of protein function. Indicating that the next generation of antibodies will be designed rather than discovered, and these designs will be aided by artificial intelligence.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 1 | NSF | $256,000 | |
Project Title: Highly resource-efficient protein engineering using machine learning |
Key People / Management
Frances Anastassacos -- Co-Founder
Surojit (Surge) Biswas
Surojit (Surge) Biswas
Company News
There are no news available.